Top-News
Pharmazeutika Großbritannien

Amarin News

Aktie
WKN:  A0NBNG ISIN:  US0231112063 US-Symbol:  AMRN
0,775 €
-0,03 €
-3,73%
03.06.24 21:17:46
Handeln Depot/Watchlist
Aktienanzahl *
407,78 Mio.
Marktkapitalisierung *
327,87 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 26.06.2023

Unternehmensmeldungen

02.08.23 - GlobeNewswire
Amarin Reports Second Quarter 2023 Financial Results
-- Company Reported Total Net Revenues of $80 Million in Second Quarter 2023; Total Net Revenues Included Net Product Revenues of $65 Million, $15 Million in License and ...
31.07.23 - GlobeNewswire
Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea
Collaboration Broadens Reach of VAZKEPA to Additional Ten Countries Leveraging Lotus’ Established Commercial and Marketing Expertise in the Region
26.07.23 - GlobeNewswire
Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress
DUBLIN, Ireland and BRIDGEWATER, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the acceptance of funded research for ...
25.07.23 - GlobeNewswire
Amarin Receives Positive Recommendation from Spanish Drug Pricing Committee for National Reimbursement of VAZKEPA® (icosapent ethyl) in Spain
-- Spain’s Drug Pricing Committee recommends reimbursement of VAZKEPA ® (icosapent ethyl) to reduce the risk of cardiovascular (CV) events in patients with high cardiovascular ...
20.07.23 - GlobeNewswire
Amarin Board of Directors Announces Executive Compensation Program for New President and CEO Patrick Holt
– Agreement Underscores Board’s Commitment to Aligning Executive Compensation with  Shareholder Returns –
18.07.23 - GlobeNewswire
Amarin Appoints Patrick Holt as President and Chief Executive Officer
DUBLIN, Ireland and BRIDGEWATER, N.J., July 18, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that the Company’s Board of Directors ...
18.07.23 - GlobeNewswire
Amarin Implements Organizational Restructuring to Strengthen the Company While Driving Patient Access to VASCEPA®/VAZKEPA® Globally
-- Focus on Gaining Access for European Patients in Remaining Geographies and Strategic Use of Commercial Resources -- -- Maximizes Cash Flow Opportunity Through ...
21.06.23 - GlobeNewswire
Amarin Announces Vascepa® (Icosapent Ethyl) Approved to Reduce Cardiovascular Risk in the Kingdom of Saudi Arabia (KSA)
-- VASCEPA ® Approved in KSA To Reduce the Risk of Cardiovascular (CV) Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 ...
01.06.23 - GlobeNewswire
Amarin Partner EddingPharm Receives Regulatory Approval for Vascepa® (Icosapent Ethyl) in Mainland China
-- VASCEPA Approved by the National Medical Products Administration (NMPA) as an Adjunct to Diet to Reduce Triglyceride Levels in Adult Patients with Severe Hypertriglyceridemia ...
12.05.23 - GlobeNewswire
Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events
— New Research Demonstrates Multifactorial Beneficial Effects of VASCEPA/VAZKEPA on Coronary Physiology and Plaque Progression —
03.05.23 - GlobeNewswire
Amarin Reports First Quarter 2023 Financial Results and Provides Business Update
-- Stable Revenue and Cash Position Due to Performance of U.S. Business and Savings from Operational Initiatives --
19.04.23 - GlobeNewswire
Amarin to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023
DUBLIN, Ireland and BRIDGEWATER, N.J., April 19, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that it will host a conference call with ...
17.04.23 - GlobeNewswire
Amarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver O’Connor to Company’s Board of Directors
DUBLIN, Ireland and BRIDGEWATER, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company’s Board of Directors ...
04.04.23 - GlobeNewswire
Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel's Ministry of Health
-- Approval of VAZKEPA® to Reduce the Risk of Cardiovascular (CV) Events in Adult Statin-​Treated Patients at High CV Risk with Elevated Triglycerides and Other High-Risk ...
16.03.23 - GlobeNewswire
Reconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA® (Icosapent Ethyl)
New Amarin Board Believes the Company Will Thrive with Proper Stewardship
06.03.23 - GlobeNewswire
Amarin Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23/WCC
--In Vitro Data Presentations Support Antithrombotic and Antioxidant Effects of EPA Compared with DHA, No Impact of Mineral Oil on Rates of LDL Oxidation -–
05.03.23 - GlobeNewswire
Amarin Announces New REDUCE-IT® Data at ACC.23/WCC Showing Benefit of VASCEPA®/VAZKEPA® (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event
--Post-​Hoc Analysis Shows IPE Significantly Reduced Risk of First, Total Ischemic Events by 37% and 36% Respectively in Patients with Recent ACS Without Increased Bleeding--
01.03.23 - GlobeNewswire
Amarin Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
-- Company Delivers Positive Free Cash Flow in Fourth Quarter 2022 Following U.S. Revenue Stabilization -- -- Previously Announced Cost Savings Program On-Track to Exceed ...
28.02.23 - GlobeNewswire
Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA® (Icosapent Ethyl) in Australia and New Zealand
DUBLIN, Ireland and BRIDGEWATER, N.J. and MELBOURNE, Australia, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) and CSL Seqirus today ...
27.02.23 - GlobeNewswire
Amarin Corporation to Present New Data Evaluating VASCEPA®/VAZKEPA® (Icosapent Ethyl) at ACC.23/WCC
Presentations on Additional REDUCE-IT® Sub-​Population, In-Vitro Data on EPA to Be Featured at the Congress

Newssuche

Videos

newspaper
29.05.24 +5,02%
Technical Trading: DAX Long Chance kurzfristig
DAX Long Typ: Turbo Open End WKN: VD5FWS Hebel: 28 Laufzeit: OpenEnd Einstieg: Market ... Mehr »